Eng

Angeliq

Quick links to important sections

Angeliq

Selected form

Method of action: Antiplasmic, Sex Hormones And Modulators Of The Genital System

Treatment option: Hormone Replacement Therapy, Osteoporosis, Prevention Of Osteoporosis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Angeliq

Quick Facts

Property	Description
Active Ingredients	Drospirenone (DRSP) and Estradiol (E2)
Form	Film-coated tablet
Pharmacological Class	Hormone Replacement Therapy (HRT); Sex Hormone Combination
Target Audience	Postmenopausal women with an intact uterus
Origin	Synthetic

What Type of Medicine is Angeliq?

Angeliq is an oral medication classified as a continuous combination Hormone Replacement Therapy (HRT), which falls under the broader pharmacological class of Sex Hormone Combinations. It is a synthetic, fixed-dose combination presented as a film-coated tablet for oral administration, requiring a prescription. This specific formulation is intended for postmenopausal women who still have an intact uterus.

The continuous administration format ensures that the same ratio of hormones is delivered daily, aiming for stable therapeutic levels.

Angeliq's Composition: Drospirenone and Estradiol

The composition includes two principal active ingredients: Estradiol (E2), which acts as the necessary hormone substitution, and Drospirenone (DRSP), a unique synthetic progestogen. The distinguishing feature of this combination is the inclusion of Drospirenone. Unlike some other progestogens, Drospirenone is characterized by its antimineralocorticoid activity and antiandrogenic activity, which differentiate it from many other compounds used in HRT.

General Purpose and Core Benefit

The overarching purpose of Angeliq is to deliver effective hormone substitution to achieve general symptom relief associated with estrogen deficiency. The core benefit of the combination resides in its engineered safety profile: while the Estradiol component addresses deficiency symptoms, the mandatory inclusion of the Drospirenone component ensures the prevention of excessive thickening of the uterine lining in women who have not had a hysterectomy. This integrated approach offers a predictable method for managing postmenopausal physiological changes while maintaining uterine health.

What side effects are possible with Angeliq?

Possible Side Effects and Safety Information

The official safety profile for Angeliq (Drospirenone/Estradiol) is structured by governmental regulatory documents (such as the FDA and EMA) to classify and communicate documented risks. This information is descriptive and is not intended as medical advice.

Serious Adverse Reactions and Systemic Risks

Official regulatory labeling includes warnings regarding increased risks of serious cardiovascular events (Vascular Disorders), including Venous Thromboembolism (VTE) (deep vein thrombosis and pulmonary embolism) and Arterial Thromboembolism (ATE) (stroke and myocardial infarction). The risks of invasive breast cancer and, in women 65 and older, probable dementia are also documented. This class of medicine also carries documented risks related to gallbladder disease and retinal vascular thrombosis (Visual Abnormalities).

Frequency-Classified Adverse Reactions

Adverse reactions are classified by frequency as observed in clinical trials, with Common effects potentially affecting up to 1 in 10 users. These frequently listed reactions span several System-Organ Classes (SOCs):

System-Organ Class (SOC)	Common Adverse Reactions (ge 1% Incidence)
Reproductive System and Breast Disorders	Breast pain or discomfort, genital tract bleeding (irregular bleeding or spotting)
Nervous System Disorders	Headache (including migraine)
Gastrointestinal Disorders	Gastrointestinal and abdominal pain, nausea

Time-Related Safety Pattern: Irregular genital bleeding or spotting is a common effect that is reported to be more frequent during the initial months of treatment and typically decreases with continued use. The risk of VTE is also noted as being higher during the first year of HRT use.

Population-Specific Safety Constraints

The medicine is contraindicated in individuals with conditions such as severe renal impairment, active liver disease, adrenal insufficiency, or a history of VTE/ATE or known malignant tumours. Due to the presence of drospirenone, a high-level safety constraint involves the risk of hyperkalaemia (elevated serum potassium) when used concurrently with certain medications, requiring caution.

Connection to the Overall Safety Profile

The official safety profile prioritizes the communication of serious systemic risks (cardiovascular hazards and malignant neoplasms) while providing classification for frequently observed adverse reactions by affected organ systems. The profile is further defined by mandatory safety constraints related to metabolic risks and underlying conditions, strictly as outlined in governmental regulatory documents.

Overdose and Emergency Response

Overdose and when to seek help

The information regarding Angeliq (Drospirenone and Estradiol) overdose is strictly derived from official government regulatory documents, outlining the documented clinical manifestations and the mandated emergency response.

Documented Overdose Manifestations

The official regulatory labeling identifies specific symptoms that may be associated with an acute overdose. These documented overdose presentations involve primarily the gastrointestinal system and the reproductive system:

Nausea
Vomiting
Sudden or unusual vaginal bleeding

Immediate Regulatory Actions

Official guidance mandates immediate action upon suspicion of an overdose or the observation of any documented manifestation. The regulatory documentation requires patients or caregivers to seek emergency medical attention and contact a poison control center or emergency room immediately. This requirement for urgent medical help is the primary mandate from authorities to manage an overdose situation effectively.

Management Stance

The official overdose section addresses the general approach to management by noting that no specific antidote is documented in the labeling for Angeliq overdose. Given this regulatory constraint, the medical focus following the mandated emergency action is centered on providing symptomatic and supportive care tailored to the patient’s clinical presentation. The regulatory profile does not contain further details on specific procedural interventions or population-specific considerations regarding overdose severity.

Therapeutic Uses of Angeliq

What Angeliq Treats: Main Uses and Benefits

Angeliq is considered relevant for easing the symptomatic relief of moderate-to-severe vasomotor symptoms associated with oestrogen deficiency. This primary use is applied in addressing pronounced physical manifestations like frequent hot flushes and disruptive night sweats. The medication is also relevant for addressing chronic, localized discomfort associated with vulvar and vaginal atrophy.

Applied in contexts marked by heightened patient distress, the treatment may assist with providing symptomatic assistance that helps patients cope more steadily with these episodes. The medication is considered relevant in clinical settings to help address symptoms that create noticeable physiological strain, including vaginal dryness, chronic irritation, and discomfort during sexual activity. Furthermore, Angeliq may be applied when additional symptomatic support for osteoporosis prevention is appropriate in high-risk postmenopausal women. This approach generally supports patients during episodes of heightened discomfort and contributes to easing the overall symptom load.

“The primary goal of this therapy is to provide symptomatic relief from the disruptive manifestations of oestrogen deficiency.”

Quick Fact: Relief for Key Symptom Domains
Vasomotor Symptoms: Reduction in hot flush frequency and intensity.
Urogenital Atrophy: Easing of vaginal dryness and irritation.
Skeletal Support: Assistance with maintaining bone density in high-risk individuals.

Eligibility and Restrictions for Use

Who Can and Cannot Use Angeliq?

Angeliq is an oral medication with strict eligibility criteria defined by regulatory authorities (FDA, EMA) that determine which patient populations may use it.

Eligibility and Exclusion Criteria

Criteria	Status	Target Population
Target Population	Allowed	Postmenopausal women with an intact uterus.
Pediatric Population	Not Indicated	Use in children is not established.
Pregnancy/Lactation	Contraindicated	Must not be used during pregnancy or breastfeeding.

Absolute Contraindications

Use of Angeliq is strictly prohibited in patients with certain high-risk medical conditions:

Malignancy: Known, suspected, or history of breast cancer or other estrogen-dependent tumors.
Thromboembolism: Active or history of venous or arterial blood clots (VTE, DVT, PE, stroke, or MI).
Organ Function: Severe renal impairment, adrenal insufficiency, or severe liver disease (including liver tumors).
Other: Undiagnosed abnormal genital bleeding or known hypersensitivity to the drug's components.

Conditional Use

Special caution and close supervision are required for patients with pre-existing conditions such as hypertension, hypertriglyceridemia, endometriosis, or uterine fibroids.

What should I know about interactions with other medicines?

The interaction profile for this medicine is defined by two primary regulatory concerns: the potential for metabolic changes and a specific pharmacodynamic risk.

Metabolic and Exposure-Altering Interactions

The clearance of both active components, Estradiol and Drospirenone, is sensitive to drugs that modulate the CYP3A4 enzyme system. Co-administration with enzyme inhibitors may result in a significant increase in the plasma concentration of the drug components, while enzyme inducers may lead to a decrease in plasma concentration. Acute ingestion of alcohol has also been documented to increase circulating estradiol levels. Strong CYP3A4 inhibitors may require serum potassium monitoring in high-risk patients.

Pharmacodynamic Interactions and Hyperkalemia Risk

Due to the antimineralocorticoid activity of Drospirenone, co-administration with other medicinal products known to increase serum potassium carries an elevated risk of hyperkalemia (high potassium levels). This category includes drugs such as ACE inhibitors, Angiotensin II Receptor Blockers (ARBs), potassium-sparing diuretics, and certain NSAIDs.

Interaction-Related Contraindications

Regulatory documents formally classify the drug as contraindicated in women with severe renal impairment, adrenal insufficiency, or hepatic impairment. This restriction is due to the potential for these conditions to severely amplify the interaction risk, either by heightening the risk of hyperkalemia or by causing a three-fold increase in the systemic exposure of Drospirenone.

Mechanism of Action

Angeliq is a combination hormone therapy containing estradiol and drospirenone. Its mechanism involves dual modulation of the endocrine and mineralocorticoid systems.

Estrogen Receptor Binding and Gene Modulation

Estradiol, the estrogen component, acts as an agonist by binding to and activating intracellular estrogen receptors (ER-alpha and ER-beta) in target tissues. This ligand-receptor complex translocates to the nucleus and modulates the transcription of specific genes. This action influences cellular processes, particularly within bone cells and vascular tissue.

Progestin Activity and Aldosterone Pathway

The progestin component, drospirenone, is a synthetic spironolactone derivative. It exerts anti-mineralocorticoid activity by acting as a competitive antagonist of aldosterone receptors. This antagonism blocks aldosterone binding, mediating a mild natriuresis (sodium excretion) in the renal tubules.

Integrated Physiological Modulation

The combined action of estradiol and drospirenone results in the modulation of markers for bone remodeling and cellular-level effects on vascular tone. This overall mechanistic profile describes the drug's simultaneous activity across multiple physiological pathways.

Dosage and Administration Information

How Angeliq is Used in Clinical Practice

Angeliq is an oral medication that is administered according to a continuous combination regimen. This approach mandates the daily and uninterrupted intake of the fixed-dose film-coated tablet to ensure stable hormone delivery.

Official Administration Guidelines

The table below summarizes the core instructions governing the use of Angeliq.

Feature	Official Instruction
Route of Administration	The medication is taken orally (by mouth).
Dosing Schedule	One tablet is taken once daily. The starting dose should be the lowest effective strength available, which may be adjusted within the labeled range based on the clinical response.
Timing	The tablet may be taken with or without food. For consistency, it should be administered at approximately the same time every day.

Procedural Structure and Adherence

The continuous regimen requires that the next 28-day pack begins immediately upon finishing the current pack, with no break in administration. If a patient is transitioning from a cyclical Hormone Replacement Therapy (HRT) product, they must complete their existing cycle before initiating Angeliq. The tablet must be swallowed whole with some liquid.

For the management of missed doses, if a dose is forgotten, it should be taken as soon as possible. However, if more than 24 hours have passed since the usual time, the missed tablet must be skipped, and the patient should resume the scheduled daily dose. The medication is not indicated for use in children or adolescents, and no specific dose adjustment is generally necessary for older adults.

Recent Clinical Evidence

Research evidence / Overview of Studies for Angeliq

Evidence for Use in Moderate-to-Severe Vasomotor Symptoms

Clinical evaluation primarily relies on short-term Randomized Controlled Trials (RCTs). These studies were used to explore how symptoms change over time, focusing on women experiencing frequently recurring hot flashes and night sweats. The main outcomes examined the frequency and severity of hot flushes, measured using patient diary cards. Studies reported statistically measured changes in the mean number of episodes between treatment and placebo groups. While research describes these short-term symptom patterns, there is a limited volume of published comparative evidence against other continuous combined hormone therapy formulations.

Evidence for Prevention of Postmenopausal Osteoporosis

Research was studied for its application in osteoporosis prevention in postmenopausal women considered to be at high risk of fracture. The main study types include Randomized Controlled Trials (RCTs) that follow participants over intermediate intervals (typically one to two years). The primary outcome was evaluated by measuring Bone Mineral Density (BMD) at the lumbar spine and total hip. Research highlights changes measured during the study period. The research on fracture outcomes relies on the surrogate measure of BMD, and dedicated, long-term trials powered specifically to measure fracture rates are uncommon for this particular formulation, meaning certainty remains low for this specific endpoint.

Clinical Research on Endometrial Protection

Clinical research focused on endometrial outcomes in women with an intact uterus. The progestogen component, drospirenone, was evaluated in dedicated substudies to study the endometrial outcomes related to the combination therapy. Studies monitored key outcomes including histological assessments (tissue examination) and patterns of vaginal bleeding. Findings indicated consistent patterns observed regarding the progestogen's effect on uterine lining thickness. While short- to intermediate-term research is characterized, studies providing very long-term data on the endometrial effects of this specific combination are less common.

What is Still Uncertain About the Research

Several aspects of the research evidence are characterized by research limitations. Comparative evidence is lacking for a direct, head-to-head comparison of this specific combination against other continuous combined hormone therapy formulations across all indications. Data for certain groups remain insufficient, particularly for older women (aged 65 and above), leading to research primarily characterizing the populations studied in the original trials. The available follow-up durations were limited for the assessment of very long-term outcomes, highlighting that evidence is still emerging in these areas.

How should Angeliq be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documents mandate specific conditions for storing and disposing of Angeliq tablets to maintain their stability and ensure safety.

Storage Classification	Requirement
Temperature	Store at Controlled Room Temperature, typically between 15 C and 30 C (59 F and 86 F).
Environment	Keep the medicine in its original, closed container, protected from excessive heat, moisture, and direct light.
Prohibited	Do not refrigerate or freeze the tablets.
Child Safety	Keep this medication out of the sight and reach of children.

Expired or unused Angeliq must be discarded according to established guidelines. Regulatory agencies advise against flushing or placing tablets directly into household trash. The preferred method for disposal is utilizing an authorized drug take-back program or following local official guidance for mixing the tablets with an undesirable substance (such as used coffee grounds) before sealing and placing in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.